J Am Pharm Assoc (2003). 2019 Sep-Oct;59(5):646-650. doi: 10.1016/j.japh.2019.06.008. Epub 2019 Jul 18.
To explore the implications of direct-to-consumer pharmacogenomic testing for community pharmacy practice.
In October 2018, the U.S. Food and Drug Administration provided approval for direct-to-consumer genetic testing company, 23andMe (Mountain View, CA), to return select pharmacogenomic test results to their customers. Given the community pharmacist's high accessibility to the public and in-depth knowledge of pharmacology, and the availability of direct-to-consumer genetic testing kits at pharmacies, it is likely that patients will present their pharmacogenomic test results to their pharmacists and expect them to incorporate those results into their care. It is important, therefore, that community pharmacists are aware of the clinical implications of these results, know where to turn for evidence-based clinical pharmacogenomics information, and be mindful of the need for confirmatory testing before changing therapy.
Community pharmacists are at the frontlines of health care, and as such will be at the frontlines of direct-to-consumer pharmacogenomic testing. In the near future, it is likely that community pharmacists will need to counsel patients on the interpretation and appropriate use of direct-to-consumer pharmacogenomic test results.
探讨直接面向消费者的药物基因组学检测对社区药房实践的影响。
2018 年 10 月，美国食品和药物管理局批准直接面向消费者的基因检测公司 23andMe（加利福尼亚州山景城）向其客户返回选定的药物基因组学检测结果。鉴于社区药剂师与公众的高度接触和对药理学的深入了解，以及药房提供直接面向消费者的基因检测试剂盒，患者很可能会向药剂师展示他们的药物基因组学检测结果，并期望他们将这些结果纳入他们的治疗中。因此，重要的是，社区药剂师应该了解这些结果的临床意义，知道在哪里可以获得基于证据的临床药物基因组学信息，并注意在改变治疗方法之前进行确认性检测的必要性。
社区药剂师处于医疗保健的前沿，因此将处于直接面向消费者的药物基因组学检测的前沿。在不久的将来，社区药剂师可能需要就直接面向消费者的药物基因组学检测结果的解释和正确使用向患者提供咨询。
